Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

What Does Abbott Laboratories (ABT) FDA Clearance Mean For Its Diabetes Device Push?

27 August 2026 · By · Wire by Fusion42

Published

27 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at finance.yahoo.com →

◆ Verified

Fusion42 · 27 August 2026 · Fusion42 review

Abbott Laboratories received FDA De Novo clearance for its Libre Duo 10 Day device, the first dual glucose and ketone monitoring wearable for U.S. patients, supporting diabetes care and integration with insulin pumps.

This Wire brief sits within Fusion42's coverage of Medtech, and 5 sources have reported it between 25 Aug 2026 and 27 Aug 2026.

◆ ◆ The Wire takeaway

Your diabetes device product now faces new standards as Abbott sets a precedent for dual analyte sensors integrating with insulin pumps. Prepare for tighter competition and pricing pressures as integrated monitoring gains regulatory momentum in the US.

◆ Coverage

5 sources · first reported 25 Aug 2026 · latest 27 Aug 2026

◆ Related on Wire

◆ Topics

Medtechfda-clearancediabetes-devicemedical-technologydigital-healthchronic-disease-care